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Abstract: Background: The purpose of this systematic literature review (SLR) was to evaluate the
accuracy of noninvasive diagnostic tools in detecting significant or advanced (F2/F3) fibrosis among
patients with nonalcoholic fatty liver (NAFL) in the US healthcare context. Methods: The SLR
was conducted in PubMed and Web of Science, with an additional hand search of public domains
and citations, in line with the PRISMA statement. The study included US-based original research
on diagnostic test sensitivity, specificity and accuracy. Results: Twenty studies were included in
qualitative evidence synthesis. Imaging techniques with the highest diagnostic accuracy in F2/F3
detection and differentiation were magnetic resonance elastography and vibration-controlled transient
elastography. The most promising standard blood biomarkers were NAFLD fibrosis score and FIB-4.
The novel diagnostic tools showed good overall accuracy, particularly a score composed of body mass
index, GGT, 25-OH-vitamin D, and platelet count. The novel approaches in liver fibrosis detection
successfully combine imaging techniques and blood biomarkers. Conclusions: While noninvasive
techniques could overcome some limitations of liver biopsy, a tool that would provide a sufficiently
sensitive and reliable estimate of changes in fibrosis development and regression is still missing.
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1. Introduction

published maps and institutional affil-

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide, affecting around a quarter of the general population and a third of the United
States (US) population [1–3].
Over time, NAFLD may progress to nonalcoholic steatohepatitis (NASH), which is
considered a more progressive form of the disease. NASH is histologically defined as hepatic
steatosis, inflammation, and ballooning (enlarged cells with rarefied cytoplasm [4]) with or
without fibrosis, caused by lipotoxicity of accumulated lipids in hepatocytes and immune
cell activation [5,6]. It is estimated that NASH affects up to 6.5% of the general population
worldwide and 3–4% of the US population [2,7]. The diagnosis is more common among obese
and diabetic patients, occurring in around 30% and 65% of cases, respectively [8].
One of the most common complications of NAFLD and NASH is liver fibrosis, occurring in more than a third of NASH patients over a 5-year period [9]. The level of liver
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fibrosis in NAFLD is commonly scored using the NASH CRN system, where fibrosis stage
0 represents no fibrosis; stage 1 demarks pericellular fibrosis; stage 2 denotes centrilobular
and periportal fibrosis; stage 3 is bridging fibrosis, and stage 4 represents cirrhosis [10].
Fibrosis stage F2 or higher (F2+) is considered significant fibrosis. Advanced fibrosis
traditionally refers to stage F3 or higher (F3+) [11].
About 8% of the general population and 13% of the high-risk population are assumed
to have undetected advanced fibrosis [12–14]. A recent population analysis of data from
National Health and Nutrition Examination Survey (NHANES) established that around
7.5% of NAFLD patients had advanced fibrosis [15]. Liver fibrosis is the most important
prognostic factor in the course of NAFLD, as it is the only pathological finding that correlates with hepatic decompensation events and liver-related mortality [16,17]. Early and
accurate diagnosis and staging of fibrosis in NAFLD and NASH patients, particularly those
with significant and advanced fibrosis (F2 and F3 stages), is necessary to determine the
patient’s prognosis and guide clinical decision-making [11,18].
Focusing on universal access to a consistently accurate and minimally invasive diagnosis of patients with significant or advanced fibrosis would ensure appropriate disease
management and a better prognosis. Studies summarizing evidence regarding noninvasive
diagnostic tests’ ability to accurately detect F2+ and F3+ fibrosis stages in NAFLD and
NASH patients are lacking within the US-based studies.
The objective of the current systematic literature review (SLR) was to collect, summarize, and interpret published evidence from US studies on the accuracy of currently
available diagnostic tests in detecting and longitudinally monitoring F2+/F3+ fibrosis
stages in NAFLD and NASH patients. As the prevalence and natural course of NAFLD
vary across the continents, races, and ethnic groups, the study focused on original research
articles conducted in the US, assuming a similar demographic distribution across the included studies and enhancing the comparability of their results. The availability of different
imaging techniques and biomarkers also varies across different countries and the study
targeted currently existing noninvasive diagnostic tests available in the US.
2. Materials and Methods
2.1. Data Sources and Selection Criteria
The key literature databases for the SLR were the Medical Literature Analysis and
Retrieval System Online (MEDLINE® ), assessed via PubMed and Web of Science (January
2016 through May 2022). As all the outcomes were considered time-sensitive and sensitive
to the evolving methodological approaches, a 6-year time constraint was applied to provide
a current update of existing literature reviews. In addition, a hand search was performed
across publicly available domains (e.g., Google Scholar) and reference lists to ensure all
relevant studies were included. Only primary original research studies were considered,
while SLRs, meta-analyses, narrative reviews, and guidelines were excluded. Selection
criteria are shown in Table 1.
Table 1. Selection criteria.
Inclusion Criteria
1.
2.
3.
4.

Published between January 2016 and May 2022
Written in English
Human studies
Original research

Exclusion Criteria
1. Studies with irrelevant outcomes
2. No full-text studies
3. In vitro studies
4. Molecular and genetic studies
5. Editorials, comments, replies, and letters to the author

2.2. Search Strategy
The search query (Table S1) was constructed to address diagnostic tool accuracy in
detection and tracking F2+ and F3+ fibrosis stages following population, intervention,
comparators, and outcomes (PICO) criteria (Table 2).
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Table 2. PICO criteria for diagnostic tools accuracy.
PICO

Population

Inclusion Criteria
1.
2.
3.
4.
5.

Patients diagnosed with NAFLD
Patients diagnosed with NASH
Patients diagnosed with significant or advanced liver fibrosis
Patients diagnosed with significant or severe liver steatosis
Patients diagnosed with liver cirrhosis

Exclusion Criteria

1. Nonhuman population

Interventions

1. Any treatment or management
2. No treatment or management

NA

Comparators

1. Any treatment or management
2. No treatment or management

NA

1.
2.
3.
4.
5.

NA

Outcomes

Restrictions

Sensitivity
Specificity
Positive predictive value
Negative predictive value
Area under the receiver operating characteristic curve

1. English language
2. Year limitation: 2016–2022

1. Genetic studies
2. Editorials
3. Letters and comments to the authors
4. Case reports
5. SLRs, meta-analyses, narrative reviews, guidelines

NAFLD—nonalcoholic fatty liver disease; NASH—nonalcoholic steatohepatitis; NA—not applicable; SLR—
systematic literature review.

The detailed search strategy and yielded hits are presented in the Supplementary
Materials (Table S1). The population included patients with NAFLD and/or NASH, also
considering the underlying stages of the disease, i.e., nonalcoholic steatosis, fibrosis, and
cirrhosis. All diagnostic tests, imaging techniques, and biomarkers were considered to
explore the accuracy of diagnostic tools in terms of sensitivity, specificity, positive and negative predictive values (PPV and NPV), and area under the receiver operating characteristic
(AUROC) curve.
2.3. Data Review and Extraction
The review was conducted in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Two independent reviewers
performed the database search, abstract and title search, and full-text screening. A third
reviewer resolved any disagreements. Predefined extraction tables were used for data
collection and evidence summary.
3. Results
The study selection process is shown in the PRISMA flow diagram (Figure 1). After
excluding duplicates, 1633 studies were title and abstract screened, 415 publications were
full-text screened, and 20 studies were selected for data extraction.
The SLR resulted in 20 original US-based studies that evaluated a wide spectrum of
noninvasive imaging modalities and biomarkers for the detection of F2+ and F3+ stage
fibrosis. The characteristics of included studies are presented in Table 3 while the full list of
diagnostic techniques is presented in Figure 2.
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1. PRISMA
diagram.
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20 original
US-based studies that evaluated a wide spectrum of
TableThe
3. Characteristics
studies.

Author

Catania et al. [19]

Author

Harrison et al. [20]

Catania et al. [19]
Jayakumar et al. [21]

Harrison et al. [20]
Ozturk et al. [22]

Year

2021

Year

2020

Ozturk et al. [22]
Tang et al. [24]

Siddiqui
etal.
al.[25]
[23]
Trowell et

Zhang et al. [26]

Tang et al. [24]

Technique

Fibrosis stage 2: 39%
Table 3. Characteristics
of included studies.
47 NAFLD

2020

2021

Study Type

Prospective study

study

patients

288 NASH
patients with
F1-F3 fibrosis

Population

FIB-4 score,
mean
Baseline
Fibrosis
(SD): 1.4 (59.3)

Imaging
VCTE
Technique

patients

13.7%Fibrosis stage
4: 2.5%

SWE

54 NASH
Fibrosis stage 2: 37%
Prospective study patients
withwith
F2- Fibrosis stage 2: 4.0% MRE
99 patients
Fibrosis stage 3: 67%
F3 fibrosis
liver
Fibrosis stage 3:
Prospective study

2020 Retrospective study
2022

Capabilities

MRI-derived LSN
Fibrosis stage 3: 25%
score
stage 4:Techniques
19%
Studies That Evaluated AccuracyFibrosis
of Imaging

Prospective study

Fibrosis stage 2: 39%
47 NAFLD
MRI-derived
2021 Prospective study 54 NASH patients Fibrosis
stage
Fibrosis
stage3:2:25% LSN score
patients
2019
Prospective study
with F2-F3
37%Fibrosis
3:
MRE
Fibrosis
stage stage
4: 19%
fibrosis
67%
288 NASH
FIB-4 score, mean
2020 Prospective study patients with F1- Fibrosis stage 2:
VCTE
(SD): 1.4 (59.3)
F3
Retrospective
116fibrosis
NAFLD
9.4%Fibrosis stage 3:

Jayakumar et al. [21] 2019
Siddiqui et al. [23]

noninvasive imaging modalities and biomarkers for the detection of F2+ and F3+ stage
Studies
That Evaluated Accuracy
of Imaging
Techniques
fibrosis.
The characteristics
of included
studies
are presented in Table 3 while the full list
Imaging
Detection
ofStudy
diagnostic
techniques
is
presented
in
Figure
2.
Type
Population
Baseline Fibrosis

Retrospective
study

transplantation
10.1%
Fibrosis
stage
Fibrosis
stage2:4:9.4%
7.1%
history

116 NAFLD
patients
91
NAFLD
patients

VCTE

Fibrosis
stage
Fibrosis
stage3:2:13.7%
7.7% SWE
Fibrosis
stage4:3:2.5%
11%
MRE
Fibrosis
stage

Fibrosis stage 4: 5.5%
99 patients with
Fibrosis stage 2: 4.0%
217 NAFLD
and
Fibrosis stage 2: 24%
liver
Retrospective
2021
stage
2021 Prospective study transplantation
non-NAFLD Fibrosis
Fibrosis
stage3:3:10.1%
13% VCTE
VCTE
study
patients
Fibrosis
stage4:4:7.1%
18%
Fibrosis
stage
history
Fibrosis stage 2: 5%
Cross-sectional
100 NAFLD Fibrosis stage 2: 7.7%
SWE,
2022
Fibrosis stage 3: 10%
91
NAFLD
study study
patients
MRE
2022 Retrospective
Fibrosis
stage
Fibrosis
stage3:4:11%
6% MRE
patients
Fibrosis stage 4: 5.5%

Significant fibrosis
Advanced fibrosis

Significant
fibrosis
Detection
Capabilities
Advanced fibrosis

Significant
fibrosis
Significant
fibrosis
Advanced
fibrosis
Advanced
fibrosis
(progression and
improvement)

Significant fibrosis
Advanced fibrosis

Significant fibrosis

Advanced
fibrosis
Significant
fibrosis
Advanced fibrosis
(progression and
Significant fibrosis
improvement)
Advanced fibrosis

Significant fibrosis
Advanced fibrosis

Advanced fibrosis

Significant fibrosis
Advanced
fibrosis
Advanced
fibrosis
Significant fibrosis
Advanced
fibrosis
Advanced
fibrosis
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Table 3. Cont.
Studies that evaluated accuracy of established fibrosis scores and biomarkers
Author

Balakrishnan et al.
[27]

Year

2021

Study Type

Retrospective
cross-sectional
study

Biomarker

Detection
Capabilities

Population

Baseline Fibrosis

99 NAFLD
patients

Fibrosis stage 0–2:
62.6%
Fibrosis stage 3–4:
37.4%
FIB-4 score,
mean (SD):
In fibrosis stage 0–2:
0.99 (0.55)
In fibrosis stage 3–4:
2.23 (1.52)

NFS,
FIB-4 index,
APRI,
BARD score

Significant fibrosis

Fibrosis stage, mean
(SD):
In no NASH: 0.6 (0.9)
In definite NASH:
1.8 (1.0)

NFS,
FIB-4 index,
APRI,
Plasma AST
levels
FibroTest

Advanced fibrosis

Bril et al. [28]

2020

Cross-sectional
study

213 T2DM
patients

Caussy et al. [29]

2019

Cross-sectional
study

156 NAFLD
patients

FIB-4 score,
mean (SD):
1.35 (1.24)

NFS,
FIB-4 index

Advanced fibrosis

Corey et al. [30]

2022

Retrospective
chart review

84 NAFLD
patients

Fibrosis stage 2: 25%
Fibrosis stage 3: 14%
Fibrosis stage 4: 10%

NFS,
FIB-4 index

Significant fibrosis

Significant
fibrosisAdvanced
fibrosis

Harrison et al. [20]

2020

Prospective study

288 NASH
patients

FIB-4 score,
mean (SD):
1.4 (59.3)

NFS,
FIB-4 index,
Plasma AST
levels,
Plasma ALT
levels,
GGT levels
ELF test

Kulkarni et al. [31]

2021

Retrospective
study

55 NAFLD
patients

Fibrosis stage 2: 20%
Fibrosis stage 3: 7.3%
Fibrosis stage 4: 3.6%

GGT levels

Significant fibrosis

NFS,
FIB-4 index,
APRI

Advanced fibrosis

Marella et al. [32]

2020

Retrospective
chart review

907 NAFLD
patients

Fibrosis stage 2:
17.9%
Advanced fibrosis:
12.8%
Fibrosis score, mean
(SD): 1.16 (1.13)
FIB-4 score, mean
(SD): 1.28 (1.75)

Nielsen et al. [33]

2021

Retrospective
database study

517 patients with
NASH and
fibrosis

Fibrosis stage 2: 21%
Fibrosis stage 3: 24%
Fibrosis stage 4: 5%

FIB-4 index,
APRI,
AST/ALT ratio

Significant
fibrosisAdvanced
fibrosis

Singh et al. [34]

2020

Retrospective
chart review

1157 adult
diabetics with
NAFLD

Fibrosis stage 0–2:
68%
Fibrosis stage 3–4:
32%

NFS,
FIB-4 index,
APRI,
AST/ALT ratio

Advanced fibrosis

Udelsman et al. [35]

2021

Retrospective
chart review

2465 patients

Fibrosis stage 3+:
3.4%

NFS,
FIB-4 index,
APRI

Advanced fibrosis

Younossi et al. [36]

2021

Retrospective
cross-sectional
study

829 NAFLD
patients

FIB-4 score, mean
(SD):
1.34 (0.97)

ELF test

Advanced fibrosis
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Table 3. Cont.
Studies that evaluated accuracy of novel biomarkers
Author

Corey et al. [30]

Bril et al. [28]

Caussy et al. [29]

Year

2022

Study Type

Retrospective
chart review

Baseline Fibrosis

Diagnostic
Technique

Detection
Capabilities

84 NAFLD
patients

Fibrosis stage 2: 25%
Fibrosis stage 3: 14%
Fibrosis stage 4: 10%

NFPP,
ADAMTSL2, and
these in
combination with
general clinical
features, FIB-4
index, or NFS

Significant fibrosis

Fibrosis stage,
mean (SD):
In no NASH: 0.6 (0.9)
In definite NASH:
1.8 (1.0)

PRO-C3,
Cohort-specific
model,
Combination of 6
biomarkers

Advanced fibrosis

Population

2020

Cross-sectional
study

213 T2DM
patients

2019

Cross-sectional
study

156 NAFLD
patients

FIB-4 score,
mean (SD):
1.35 (1.24)

Prognostic factor
model,
Top 10 metabolite
panel

Advanced fibrosis

FIB-4 score,
mean (SD):
1.4 (59.3)

CK-18 fragment
M30,
CK-18 fragment
M65,
MCP-1

Significant
fibrosisAdvanced
fibrosis

Harrison et al. [20]

2020

Prospective study

288 NASH
patients

Kulkarni et al. [31]

2021

Retrospective
study

55 NAFLD
patients

Fibrosis stage 2: 20%
Fibrosis stage 3: 7.3%
Fibrosis stage 4: 3.6%

Scoring system

Significant fibrosis

Nielsen et al. [33]

2021

Retrospective
database study

517 patients with
NASH and
fibrosis

Fibrosis stage 2: 21%
Fibrosis stage 3: 24%
Fibrosis stage 4: 5%

PRO-C3, ADAPT
score

Significant
fibrosisAdvanced
fibrosis

238 NAFLD
patients

Fibrosis stage 2:
11.3%
Fibrosis stage 3: 9.7%
Fibrosis stage 4: 7.6%
FIB-4 score, mean
(SD): 1.5 (1.4)

MEFIB index

Significant fibrosis

585 NAFLD
patients

Fibrosis stage 2:
20.6%
Fibrosis stage 3:
20.7%
Fibrosis stage 4:
10.4%

FAST score

Significant fibrosis

Jung et al. [37]

Woreta et al. [38]

2021

2022

Prospective study

Retrospective
study
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Fibrosis stage 4: 10.4%

Figure 2. Summary of diagnostic modalities obtained in the SLR.
Figure 2. Summary of diagnostic modalities obtained in the SLR.

3.1.
3.1. Imaging
Imaging Techniques
Techniques
The
SLR
identified
eight
studies
that explored
the diagnostic
accuracy
and
The SLR identified
eight
studies
that explored
the diagnostic
accuracy and
capabilities
capabilities
of imagingintechniques
in terms of
significant
(F2+ fibrosis
stages) (F3+
and
of imaging techniques
terms of significant
(F2+
fibrosis stages)
and advanced
advanced
(F3+ fibrosis
fibrosisdetection
stages) fibrosis
detection
(Table 3).
The diagnostic
of
fibrosis stages)
(Table 3).
The diagnostic
accuracy
of imagingaccuracy
techniques
imaging
techniques
in detection
of significant
andisadvanced
is presented
in detection
of significant
and advanced
fibrosis
presentedfibrosis
in Tables
4 and 5. in Tables
4 and 5.
Table 4. Diagnostic accuracy of imaging techniques for significant fibrosis.
Table 4. Diagnostic accuracy of imaging techniques for significant fibrosis.
Vibration-Controlled Transient Elastography

Source

Source
Harrison et al. [20]
Harrison et al. [20]
Siddiqui et al. [23]

Siddiqui et al. [23]

Vibration-Controlled Transient Elastography
Sensitivity
Specificity
PPV
Cutoff
Sensitivity
Specificity
7.3 kPa
89.0%
33.0%
77.0%
7.3 kPa
89.0%
33.0%
7.4 kPa
90.0%
60.0%
38.0%
7.4 kPa
90.0%
60.0%
10.5 kPa
81.0% 81.0%
83.0%
10.5 kPa
83.0% 57.0%
13.5 kPa
67.0% 67.0%
90.0%
13.5 kPa
90.0% 67.0%
Shear Wave Elastography
Cutoff

PPV
77.0%
38.0%
57.0%
67.0%

NPV

NPV
56.0%
56.0%
96.0%
96.0%
94.0%
94.0%
91.0%
91.0%

AUROC

AUROC
0.630
0.630
0.870
0.870
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Table 4. Cont.
Shear Wave Elastography
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Ozturk et al. [22]

8.4 kPa

77.0%

66.0%

-

-

0.730

1.49 m/s

90.5%

43.0%

29.7%

94.4%

1.79 m/s

47.6%

91.1%

58.8%

86.7%

Zhang et al. [26]

0.810

Magnetic Resonance Elastography
Source
Zhang et al. [26]

Cutoff

Sensitivity

Specificity

PPV

NPV

2.77 kPa

90.5%

84.8%

61.3%

97.1%

3.06 kPa

81.0%

91.1%

70.8%

94.7%

AUROC
0.940

Magnetic Resonance Imaging-Derived Liver Surface Nodularity Score
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Catania et al. [19]

2.23

72.0%

62.0%

-

-

0.800

Abbreviations: PPV—positive predictive value; NPV—negative predictive value; AUROC—area under the
receiver operating characteristic curve.

Table 5. Diagnostic accuracy of imaging techniques for advanced fibrosis.
Vibration-Controlled Transient Elastography
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

11.5 kPa

56.0%

71.0%

65.0%

63.0%

0.650

10.5 kPa

94.0%

83.0%

53.0%

99.0%

10.5 kPa

90.0%

83.0%

53.0%

99.0%

13.3 kPa

Siddiqui et al. [23]

Trowell et al. [25]

0.940

82.0%

90.0%

64.0%

96.0%

11.9 kPa

1

75.0%

81.5%

65.4%

87.5%

0.850

11.9 kPa

2

73.7%

74.5%

53.8%

87.5%

0.780

Shear Wave Elastography
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Ozturk et al. [22]

8.4 kPa

84.0%

70.0%

-

-

0.820

1.46 m/s

93.8%

39.3%

39.3%

97.1%

1.78 m/s

62.5%

90.5%

55.6%

92.7%

Zhang et al. [26]

0.850

Magnetic Resonance Elastography
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

93.0%

95.0%

78.0%

99.0%

0.939

3.65 kPa 4

93.0%

95.0%

78.0%

99.0%

0.947

5

93.0%

93.0%

74.0%

99.0%

0.940

2.77 kPa

93.8%

81.0%

81.0%

98.6%

3.17 kPa

81.3%

90.5%

61.9%

96.2%

3.6 kPa
Tang et al. [24]

3

3.65 kPa
Zhang et al. [26]

0.950

Magnetic Resonance Imaging-Derived Liver Surface Nodularity Score
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Catania et al. [19]

2.44

81.0%

88.0%

-

-

0.860

Abbreviations: PPV—positive predictive value; NPV—negative predictive value; AUROC—area under the
receiver operating characteristic curve. 1 Reported results are obtained from the training cohort. 2 Reported
results are obtained from the validation cohort. 3 Diagnostic accuracy at Center 1. 4 Diagnostic accuracy at Center
2. 5 Diagnostic accuracy of automated liver stiffness analysis.
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3.1.1. Vibration-Controlled Transient Elastography (VCTE)
In a randomized clinical trial that tested baseline performance of different noninvasive
diagnostic techniques, Harrison et al. reported low predictive value of VCTE in differentiating fibrosis stages in NASH patients with biopsy-proven F1–F3 fibrosis (AUROC 0.630
for F2+, 0.650 for F3+) [20]. On the other hand, in a prospective study of liver transplant
recipients, Siddiqui et al. found that VCTE detects significant and advanced fibrosis with
reliable accuracy. By fixing the sensitivity at 90%, the authors demonstrated its potential to
be used as a rule-out tool for significant fibrosis in case of negative results (cutoff 7.4 kPa)
among post-liver transplantation patients. It was shown that VCTE with cutoff value
of 10.5 kPa was a better ruling-out technique for advanced fibrosis than for significant
fibrosis (AUROC 0.940 vs. 0.870, respectively). Still, when the specificity was fixed at 90%,
the method yielded a low PPV for both significant and advanced fibrosis (67% and 64%),
implying that the tool cannot be reliably used for ruling in the higher-grade fibrosis stages
in diagnostic practice [23]. Similarly, a single-center retrospective cohort study by Trowel
et al. reported reliable accuracy and rule-out potential of VCTE in advanced fibrosis [25].
3.1.2. Shear Wave Elastography (SWE)
In a retrospective analysis by Ozturk et al., SWE with a cutoff value of 8.4 kPa performed well in detecting significant and advanced fibrosis in patients with suspected or
diagnosed NAFLD, concluding that SWE may be useful in detecting the patients at risk of
liver morbidity and mortality [22]. Zhang et al. reported better diagnostic performance
of SWE in detecting significant and advanced fibrosis among patients with diagnosed or
suspected NAFLD. This cross-sectional study pointed out the potential of using SWE as
a rule-out diagnostic tool for F2+ and F3+ fibrosis stages (cutoff 1.49 m/s, and 1.46 m/s,
respectively). However, using cutoffs with specificity ≥ 90% for significant and advanced
fibrosis incorrectly classified approximately every second patient with a positive test result
(58.8% and 55.6% PPV, respectively) due to the small prevalence of the condition in the
tested sample [26].
3.1.3. Magnetic Resonance Elastography (MRE)
Zhang et al. showed that MRE at a 2.77 kPa cutoff value (for both fibrosis stages) could
be used as an ideal rule-out diagnostic tool, while at a fixed specificity of ≥90%, it performed
significantly better than SWE in accurately detecting patients with fibrosis F2+ and F3+
stages. Still, the study concluded that neither of the two techniques performed well enough
to replace biopsy in detecting significant and advanced fibrosis [26]. In a retrospective
analysis of patients with suspected or diagnosed NAFLD from two medical centers, Tang
et al. reported almost perfect diagnostic accuracy of MRE in detecting advanced fibrosis
(cutoffs of 3.6 kPa and 3.65 kPa). Based on these results, the MRE correctly detected the
absence of F3+ fibrosis in nearly all patients, with lower but acceptable rule-in potential [24].
Jayakumar et al. reported higher accuracy of MRE in tracking fibrosis improvement
than progression among patients diagnosed with F2 and F3 fibrosis stages at ≥0% reduction
cutoff (AUROC 0.790). The tool performed better in detecting improvement among F3 patients
than F2 patients, with a high difference in specificity (86% and 33%, respectively) but similar
sensitivity (69% and 60%, respectively). The accuracy of detecting F2 and F3 fibrosis progression
was modest at ≥0% improvement cutoff (AUROC 0.570), but a high NPV value (88%) implies
the method can still be used to rule out the fibrosis progression [21].
3.1.4. Magnetic Resonance Imaging-Derived Liver Surface Nodularity (MRI-Derived
LSN) Score
A single-arm prospective study performed by Catania et al. showed that MRI-derived
LSN score was a reliable tool in detecting significant and advanced fibrosis among patients
with NAFLD (AUROCs 0.800 for F2+, 0.860 for F3+) [19].
Diagnostic accuracy of imaging techniques is presented in Table 4 for significant
fibrosis and Table 5 for advanced fibrosis.
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3.2. Established Fibrosis Scores and Biomarkers
Our SLR identified 11 studies that reported diagnostic accuracy of established general
scores and biomarkers in detecting significant and advanced fibrosis (Table 3). Tables 6 and 7
summarize the diagnostic performance of the established scores and biomarkers in detecting significant and advanced fibrosis.
Table 6. Diagnostic accuracy of established scores and biomarkers in detecting significant fibrosis.
NAFLD Fibrosis Score
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Corey et al. [30]

-

36%

85%

67%

62%

0.640

Harrison et al. [20]

0.9

66%

52%

77%

38%

0.600

Fibrosis-4 index
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Corey et al. [30]

-

48%

88%

76%

68%

0.700

Harrison et al. [20]

1.3

64%

70%

84%

44%

0.690

Nielsen et al. [33]

>1.12

71%

62%

65%

69%

0.710

AST to Platelet Ratio Index
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Nielsen et al. [33]

>0.42

57%

67%

63%

61%

0.660

Enhanced Liver Fibrosis test
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

−0.2

62%

68%

83%

42%

0.690

GGT levels
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

70.0 U/L

40%

72%

79%

32%

0.560

Kulkarni et al. [31]

65 U/L

66%

76%

-

-

-

AST/ALT ratio
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Nielsen et al. [33]

>0.56

90%

25%

54%

71%

0.580

Specificity

PPV

NPV

AUROC

68%

82%

38%

0.630

AST levels
Source

Cutoff

Sensitivity

Harrison et al. [20]

42.0 U/L

57%

ALT levels
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

54.0 U/L

53%

60%

77%

33%

0.550

Abbreviations: NAFLD—nonalcoholic fatty liver disease; PPV—positive predictive value; NPV—negative predictive value; AUROC—area under the receiver operating characteristic curve; GGT—gamma-glutamyl transferase;
AST—aspartate transaminase; ALT—alanine transaminase.

Table 7. Diagnostic accuracy of established scores and biomarkers for detecting advanced fibrosis.
NAFLD Fibrosis Score
Source
Balakrishnan et al. [27]

Cutoff

Sensitivity

Specificity

PPV

NPV

≥−1.455

81.1%

66.1%

58.8%

85.4%

≥0.676

32.4%

95.2%

80.0%

70.2%

AUROC
0.790
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Table 7. Cont.
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

<−1.455 and >0.676

91%

40%

26%

95%

−0.053

68%

55%

21%

90%

Caussy et al. [29]

-

90%

59%

28%

97%

0.840

Harrison et al. [20]

0.9

71%

48%

57%

63%

0.580

Marella et al. [32]

>0.675

57%

84%

35%

93%

0.810

>0.676

63.7%

70%

49.8%

80.5%

≥(−1.455)

94.6%

16.9%

34.7%

87.1%

<−1.455

85%

38%

5%

99%

>0.675

40%

85%

9%

98%

PPV

NPV

Bril et al. [28]

Singh et al. [34]

Udelsman et al. [35]

AUROC
0.640

0.720

0.720

Fibrosis-4 Index
Source

Cutoff

Sensitivity

Specificity

AUROC

≥1.3

56.8%

77.4%

60%

75%

≥2.67

40.5%

100%

100%

73.8%

<1.45 and >3.25

33%

99%

80%

94%

1.666

68%

75%

31%

93%

Caussy et al. [29]

-

90%

39%

21%

96%

0.780

Harrison et al. [20]

1.3

69%

64%

65%

68%

0.670

Marella et al. [32]

> 2.67

29%

98%

66%

90%

0.880

Nielsen et al. [33]

>1.12

87%

59%

46%

92%

0.790

>2.67

44.1%

93%

74.5%

78.3%

≥1.45

72.6%

64.4%

48.5%

83.6%

>1.30

58%

86%

13%

98%

>2.67

21%

99%

55%

97%

Balakrishnan et al. [27]

Bril et al. [28]

Singh et al. [34]

Udelsman et al. [35]

0.770

0.780

0.770

0.790

AST to Platelet Ratio Index
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Balakrishnan et al. [27]

≥1

48.7%

88.7%

72%

74.3%

0.700

<0.5 and >1.5

31%

99%

67%

94%

0.423

84%

75%

36%

96%

Marella et al. [32]

>1.5

14%

98%

47%

89%

0.830

Nielsen et al. [33]

>0.34

79%

51%

39%

86%

0.680

>1.5

16.5%

97.4%

74.7%

71.7%

≥1

27.9%

94.7%

70.9%

74%

>0.98

24%

99%

65%

97%

0.810

Bril et al. [28]

Singh et al. [34]
Udelsman et al. [35]

0.860

0.740

BARD Score
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Balakrishnan et al. [27]

≥2

75.7%

59.7%

52.8%

80.4%

0.760
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Table 7. Cont.
Enhanced Liver Fibrosis Test
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

−0.1

67%

63%

63%

66%

0.680

57.5%

88.9%

62.5%

88.6%

19.5%

99.1%

88.0%

79.2%

58.2%

84.1%

43.0%

90.7%

17.7%

99.5%

87.5%

85.4%

9.8
Younossi et al. [36]

1

11.3

1

9.8 2
11.3

2

0.810

0.790

FibroTest
Source
Bril et al. [28]

Cutoff

Sensitivity

Specificity

PPV

NPV

<0.3 and >0.7

17.0%

98.0%

40.0%

92.0%

0.353

64.0%

74.0%

30.0%

92.0%

AUROC
0.700

GGT Levels
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

68.0 U/L

49%

72%

63%

59%

0.620

AST/ALT Ratio
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Nielsen et al. [33]

>0.78

63%

64%

42%

81%

0.680

>1.4

27.4%

84.2%

44.6%

71.5%

≥1

60.7%

53.3%

37.6%

74.5%

Cutoff

Sensitivity

Specificity

PPV

NPV

40 U/L

77%

81%

41%

96%

38 U/L

84%

79%

40%

97%

37 U/L

73%

52%

60%

67%

0.660

Singh et al. [34]

0.620

AST Levels
Source
Bril et al. [28]
Harrison et al. [20]

AUROC
0.850

ALT Levels
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

68.0 U/L

41%

74%

61%

56%

0.580

Abbreviations: NAFLD—nonalcoholic fatty liver disease; PPV—positive predictive value; NPV—negative predictive value; AUROC—area under the receiver operating characteristic curve; AST—aspartate transaminase;
ALT—alanine transaminase; BARD score—BMI. AST, ALT, and diabetes mellitus presence; GGT—gammaglutamyl transferase; BMI—body-mass index; 1 biopsy was used as a reference tool; 2 vibration-controlled
transient elastography was used as a reference tool.

3.2.1. NAFLD Fibrosis Score (NFS)
In general, the low diagnostic accuracy of NFS was reported in the included studies
with AUROC values ranging from 0.600 to 0.640 for the detection of significant fibrosis [20,30].
Harrison et al. reported a relatively low sensitivity (66%) and specificity (52%) of NFS in
significant fibrosis detection among NASH patients at a cutoff value of 0.9. Corey et al.
reported an 85% specificity rate with a 67% PPV for NFS [30]. As for advanced fibrosis,
Harrison et al. reported even lower NFS accuracy with an AUROC of 0.580 [20]. On the
other hand, in the studies by Caussy et al. and Marella et al., AUROC values of NFS for
advanced fibrosis ranged from 0.810 to 0.840 [29,32]. Bril et al. and Singh et al. reported
slightly lower AUROC values (0.640–0.720) among patients with diabetes mellitus (30, 36).
Udelsman et al. demonstrated good accuracy of NFS in the advanced fibrosis detection
with almost perfect NPV values for both reported cutoffs (98% and 99%, respectively)
among patients who underwent liver biopsy before bariatric surgery, indicating it may
be a reliable tool for ruling out advanced fibrosis [35], while Balakrishnan et al. reported
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good prognostic ability of NFS in detection of advanced fibrosis among a predominantly
Hispanic population (AUROC of 0.790) [27].
3.2.2. Fibrosis-4 (FIB-4) Index
In Corey et al., the FIB-4 index performed well in detecting significant fibrosis with a
high specificity (88%), PPV (76%), and AUROC of 0.700 [30]. Harrison et al. and Nielsen
et al. reported good diagnostic accuracy of the FIB-4 index at a cutoff value of 1.3 for
detecting significant and advanced fibrosis with AUROC 0.670–0.790 among patients with
NASH [20,33]. Other studies established slightly better accuracy of FIB-4 index in the
advanced fibrosis detection among NAFLD patients (AUROC of 0.770–0.880) [27,29,32].
Very high specificity reported in the study by Udelsman et al. indicates that FIB-4 would
be a reliable noninvasive tool to rule in patients with advanced fibrosis [35]. Similarly, Bril
et al. and Singh et al. showed a good diagnostic accuracy of the FIB-4 among patients with
diabetes [28,34].
3.2.3. AST to Platelet Ratio Index (APRI)
APRI showed a low diagnostic accuracy for the detection of significant fibrosis with a
general AUROC of 0.660 with a cutoff value > 0.42 [33]. In contrast, for the detection of advanced fibrosis, APRI yielded good diagnostic accuracy (AUROC ranged from 0.680–0.860),
with high specificity (75–99%), indicating that it may be a reliable tool to rule in patients
with advanced fibrosis [27,28,32,34,35].
3.2.4. BARD Score
Balakrishnan et al. reported moderate diagnostic accuracy of the BARD score in
detecting advanced fibrosis among predominantly Hispanic NAFLD patients, with a high
sensitivity rate, which indicated the BARD score would be reliable for ruling out advanced
fibrosis [27].
3.2.5. Enhanced Liver Fibrosis (ELF) Test
In the study by Harrison et al., the ELF test demonstrated satisfying accuracy for
detecting significant (cutoff −0.2) and advanced fibrosis (cutoff −0.1) among NASH patients [20]. Younossi et al. reported very high specificity of the ELF test and good reliability
in ruling in patients with advanced fibrosis (cutoffs 9.8 and 11.3) among NAFLD patients
with biopsy and VCTE as reference tools [36].
3.2.6. FibroTest
The FibroTest has demonstrated modest accuracy in the detection of advanced fibrosis
among patients with NAFLD [28]. At cutoff values < 0.3 and >0.7, the FibroTest demonstrated very high specificity, showing its potential for ruling in patients with advanced
fibrosis. The main limitation of the FibroTest is the results between 0.3 and 0.7 would be
unclassified [28].
3.2.7. Gamma-Glutamyl Transferase (GGT) Levels
Harrison et al. reported low diagnostic accuracy of serum GGT levels in detecting
significant and advanced fibrosis among NASH patients [20]. Kulkarni et al. demonstrated
slightly better accuracy in detecting significant fibrosis in terms of sensitivity and specificity
among NAFLD patients [31], but in general, GGT was marked as a biomarker with low
diagnostic accuracy for fibrosis detection.
3.2.8. Aspartate Aminotransferase/Alanine Aminotransferase Ratio (AST/ALT Ratio)
Nielsen et al. assessed the diagnostic accuracy of the AST/ALT ratio for detecting
significant and advanced fibrosis among patients with NASH and liver fibrosis [33]. The
study denoted very high sensitivity (90%) with a cutoff value > 0.56 and suggested this
biomarker could be reliable for ruling out significant fibrosis [33]. In contrast, the same
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study showed a low diagnostic accuracy of AST/ALT ratio in advanced fibrosis detection
with a cutoff value > 0.78 [33], while Singh et al. demonstrated even lower diagnostic
accuracy among T2DM patients with NAFLD [34].
3.2.9. AST and ALT Levels
In Harrison et al.’s study, AST and ALT levels demonstrated low accuracy for detecting significant and advanced fibrosis among NASH patients (AUROC ranged from
0.550–0.660) [20]. On the other hand, Bril et al. reported very good accuracy of plasma AST
levels in detecting advanced fibrosis among T2DM patients (AUROC of 0.850) at cutoff
points of 40 U/L and 38 U/L [28].
Diagnostic accuracy of established fibrosis scores and biomarkers is presented in
Table 6 for significant fibrosis and Table 7 for advanced fibrosis.
3.3. Novel Biomarkers
The SLR identified eight US studies that evaluated the diagnostic accuracy of novel
biomarkers in the detection of significant or advanced fibrosis (Table 3). The diagnostic
capabilities of novel biomarkers in the detection of significant and advanced fibrosis are
presented in Tables 8 and 9.
Table 8. Diagnostic performance of novel biomarkers in the detection of significant fibrosis.
Cytokeratine-18 Fragment M30
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

260 U/L

90%

26%

76%

50%

0.560

Cytokeratine-18 Fragment M65
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

545 U/L

90%

29%

77%

54%

0.580

Procollagen Type-III N-Terminal Peptide
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Nielsen et al. [33]

19.65 ng/mL

45%

86%

76%

61%

0.700

Monocyte Chemoattractant Protein 1
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

497.2

21%

87%

80%

30%

0.520

NAFLD Fibrosis Protein Panel
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Corey et al. [30]

-

64%

86%

78%

76%

0.830

NAFLD Fibrosis Protein Panel with General Clinical Features
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Corey et al. [30]

-

70%

93%

88%

80%

0.870

NAFLD Fibrosis Protein Panel and FIB-4 Index
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Corey et al. [30]

-

73%

85%

80%

80%

0.870

NAFLD Fibrosis Protein Panel and NFS
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Corey et al. [30]

-

76%

85%

81%

81%

0.870
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Table 8. Cont.
A Disintegrin and Metalloproteinase with Thrombospondin Motifs like 2
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Corey et al. [30]

-

58%

91%

83%

74%

0.830

A Disintegrin and Metalloproteinase with Thrombospondin Motifs like 2 with FIB-4
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Corey et al. [30]

-

67%

85%

79%

76%

0.830

A Disintegrin and Metalloproteinase with Thrombospondin Motifs like 2 with NFS
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Corey et al. [30]

-

58%

90%

83%

73%

0.830

Kulkarni Model
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Kulkarni et al. [31]

6.13

83.3%

94.6%

-

-

0.945

Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Nielsen et al. [33]

>6.15

64.0%

75.0%

71.0%

68.0%

0.760

ADAPT Score

MEFIB Index
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Jung et al. [37]

MRE ≥ 3.3 kPa
and FIB-4 index
≥ 1.6

50.0%

99.4%

83.2%

83.2%

0.900

AUROC

FAST Score
Source

Woreta et al. [38]

Cutoff

Sensitivity

Specificity

PPV

NPV

0.35

91.0%

50.0%

51.0%

90.0%

0.67

52.0%

87.0%

69.0%

76.0%

0.38

90.0%

53.0%

52.0%

90.0%

0.72

44.0%

90.0%

72.0%

73.0%

0.807

Abbreviations: NAFLD—nonalcoholic fatty liver disease; PPV—positive predictive value; NPV—negative predictive value; AUROC—area under the receiver operating characteristic curve; ADAPT score—PRO-C3, presence of
type 2 diabetes, platelet count, and age; PRO-C3—procollagen type-III N-terminal peptide; NFS—NAFLD fibrosis
score; Kulkarni model—BMI, GGT, 25-OH-vitamin D and platelet count; MEFIB index—MRE in combination
with FIB-4 index; FAST score—liver stiffness measurement and controlled attenuation parameter measured by
VCTE (FibroScan) and serum levels of aspartate transaminase; MRE—magnetic resonance elastography; FIB-4
index—Fibrosis-4 index; VCTE—vibration-controlled transient elastography; general clinical features -age, BMI,
sex, and diabetes status; GGT—gamma-glutamyl transferase levels.

Table 9. Diagnostic performance of novel biomarkers in the detection of advanced fibrosis.
Cytokeratine-18 Fragment M30
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

260 U/L

94%

23%

55%

80%

0.590

Cytokeratine-18 Fragment M65
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

545 U/L

95%

25%

56%

83%

0.600
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Table 9. Cont.
Procollagen Type-III N-Terminal Peptide
Source
Bril et al. [28]
Nielsen et al. [33]

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

20 ng/mL

50%

96%

67%

92%

13.2 ng/mL

88%

80%

43%

97%

13.45 ng/mL

77%

59%

44%

87%

0.730

0.900

Monocyte Chemoattractant Protein 1
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Harrison et al. [20]

245.1

93%

14%

52%

67%

0.510

Cohort-Specific Model (Serum CK-18, Fasting Insulin, Platelets Count, Sex, HbA1c)
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

Bril et al. [28]

<−2.613 and
>1.015

88%

86%

57%

97%

−1.369

80%

83%

45%

96%

AUROC
0.860

Prognostic Factor Model
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Caussy et al. [29]

-

90%

37%

20%

95%

0.840

Top 10 Metabolite Panel
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Caussy et al. [29]

-

90%

79%

43%

98%

0.940

ADAPT Score
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Nielsen et al. [33]

>6.16

78%

69%

50%

88%

0.800

Combination of 6 Biomarkers
Source

Cutoff

Sensitivity

Specificity

PPV

NPV

AUROC

Bril et al. [28]

PRO-C3—13.2
ng/mL
APRI—0.423
AST—38
units/L
FIB-4
index—1.666
FibroTest—
0.353
NFS −0.053

71%

94%

68%

95%

0.910

Abbreviations: PPV—positive predictive value; NPV—negative predictive value; AUROC—area under the receiver operating characteristic curve; CK-18—cytokeratine-18; prognostic factor model—score includes platelet
count, international normalized ratio, HbA1c, and alkaline phosphatase based on backward stepwise elimination
of factors associated with advanced fibrosis; serum top 10 metabolites panel—5 alpha-androstan-3 beta monosulfate, pregnanediol-3-glucuronide, androsterone sulfate, epiandrosterone sulfate, palmitoleate, dehydroisoandrosterone sulfate, 5 alpha-androstan-3 beta disulfate, glycocholate, taurine, and fucose; ADAPT score—PRO-C3,
presence of type 2 diabetes, platelet count, and age; combination of 6 biomarkers—PRO-C3, APRI, AST, FIB-4
index, FibroTest, and NFS; PRO-C3—procollagen type-III N-terminal peptide; APRI—AST to platelet ratio index;
AST—aspartate transaminase; NFS—NAFLD fibrosis score; FIB-4 index—Fibrosis-4 index; NAFLD—nonalcoholic
fatty liver disease.

3.3.1. Cytokeratine-18 (CK-18) Fragments M30 and M65
Harrison et al. evaluated the diagnostic accuracy of CK-18 fragments M30 and M65
and demonstrated high sensitivity for significant and advanced fibrosis detection [20].
The low specificity (<30%) indicates restricted ability for ruling in F2+ fibrosis at the
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defined cutoffs. For advanced fibrosis, CK-18 fragments demonstrated overall low accuracy
(AUROC 0.590–0.600).
3.3.2. Procollagen Type-III N-Terminal Peptide (PRO-C3)
Nielsen et al. reported that plasma PRO-C3 has satisfying diagnostic accuracy
(AUROC = 0.700) for the detection of significant fibrosis among NASH patients with high
specificity (86%) and rule-in potential [33]. For advanced fibrosis, AUROC of 0.730 was
reported [33]. The cross-sectional study by Bril et al. identified PRO-C3 as one of the
most reliable biomarkers for advanced fibrosis detection with a specificity of 96% and
0.900 AUROC at 20 ng/mL cutoff point [28].
3.3.3. Monocyte Chemoattractant Protein 1 (MCP-1)
MCP-1 demonstrated modest diagnostic accuracy for the detection of significant and
advanced fibrosis among NASH patients (AUROC of 0.520 and 0.510, respectively) [20]. In contrast, the high specificity of the MCP-1 biomarker reported in the same study indicated it could
be reliable to rule in patients with significant advanced fibrosis (87% and 93%, respectively).
3.3.4. NAFLD Fibrosis Protein Panel (NFPP) and a Disintegrin and Metalloproteinase with
Thrombospondin Motifs like 2 (ADAMTSL2)
A retrospective study reported on two novel biomarkers for the detection of significant
fibrosis among NAFLD patients, ADAMTSL2, and a combination of 8 sensitive proteins—
NFPP [30]. Both biomarkers showed high diagnostic accuracy with AUROC of 0.830 for
the detection of significant fibrosis. Additionally, the combination of NFPP with general
clinical features (age, BMI, sex, and diabetes status), or with FIB-4 index or NFS improved
the diagnostic accuracy of NFPP (AUROC 0.870) [30].
3.3.5. Kulkarni Model
A large 10-year retrospective study of pediatric patients who underwent liver biopsy
identified the strongest predictors of significant liver fibrosis. The model included body
mass index, vitamin D, platelet count, and GGT and resulted in a very good predicting
ability with sensitivity and specificity of more than 80% and AUROC of 0.944 [31].
3.3.6. ADAPT Score
ADAPT score, based on the PRO-C3 levels, T2DM, platelet count, and age demonstrated satisfying accuracy in the detection of significant and advanced fibrosis among
patients with definite NASH and liver fibrosis (AUROC 0.760 for F2+, 0.800 for F3+) [33].
3.3.7. MEFIB Index
MEFIB index was determined using MRE with a cutoff value ≥ 3.3 kPa and FIB-4
index with a cutoff value ≥ 1.6 and provided a very high accuracy level for the detection of
significant fibrosis [37]. Almost perfect specificity suggested this tool would be reliable to
rule in NAFLD patients with significant fibrosis.
3.3.8. FAST Score
FAST score combines liver stiffness measurement (LSM) and controlled attenuation
parameter measured by VCTE (e.g., FibroScan) and serum levels of AST [38]. Overall, good
accuracy of the FAST score was demonstrated in detecting definite NASH (NAFLD activity
score ≥ 4 and significant fibrosis) among patients with NAFLD. A FAST score with lower
cutoff values (0.35 and 0.38) demonstrated good ability to rule out F2+ [38].
3.3.9. Cohort-Specific Model and Combination of 6 Biomarkers
The model included serum CK-18, fasting insulin, platelet count, sex, and HbA1c
demonstrated good performance with an AUROC of 0.860 for advanced fibrosis detection
among patients with T2DM [28]. A combination of 6 noninvasive tools (PRO-C3, APRI,
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AST, FIB-4 index, FibroTest, and NFS) showed very reliable performance with an AUROC
of 0.910 in detecting advanced fibrosis among NAFLD patients with T2DM [28].
3.3.10. Prognostic Factor Model
The model combining alkaline phosphatase, HbA1c, platelet count, and international
normalized ratio performed well in detecting advanced fibrosis among NAFLD patients.
However, high sensitivity and lower specificity indicated this noninvasive panel would be
only reliable in ruling out patients with advanced fibrosis [29].
3.3.11. Top 10 Metabolite Panel
The combination of 10-serum metabolites including lipids, amino acids, and carbohydrates (5α-androstane-3β monosulfate, pregnanediol-3-glucuronide, androsterone sulfate,
epiandrosterone sulfate, palmitoleate, dehydroisoandrosterone sulfate, 5α-androstane-3β
disulfate, glycocholate, taurine, and fucose) detected advanced fibrosis with high accuracy
(AUROC 0.940) among NAFLD patients [29].
Accuracy of novel diagnostic tools is presented in Table 8 for significant fibrosis and
Table 9 for advanced fibrosis.
4. Discussion
This SLR provides a comprehensive current overview of diagnostic tools for detection
and monitoring of NASH-related liver fibrosis staging based on the summarized evidence
from the US studies. The diagnostic accuracy was validated against liver biopsy as a
standard diagnostic tool in all studies, except for the Caussy et al. study where both liver
biopsy and MRE were used [29], and that of Younossi et al. where VCTE and biopsy were
reference tools [36].
There is a remarkable shift in the diagnostic pathways from biopsy as the reference
standard to novel, less invasive techniques, imaging methods, and blood biomarkers. Still,
the collected evidence implies there is no perfect noninvasive tool capable of capturing and
tracking all the aspects of the complex pathological process resulting in fatty liver, liver
fibrosis, and cirrhosis. Liver biopsy often remains necessary in particular for clinical trials.
VCTE (FibroScan® ) is a noninvasive ultrasound-based imaging method that measures
the speed of passage of acoustic shear waves through the liver tissue to estimate liver
stiffness. Our SLR provides collected evidence on good overall accuracy of VCTE. A
prospective study conducted on liver transplant recipients by Siddiqui et al. reported high
accuracy of LSM in the detection of significant fibrosis (AUROC of 0.870) and advanced
fibrosis (AUROC of 0.940). Still, the PPV values lower than 60% indicate that the tool
should be used carefully when ruling in the conditions [23]. Similar conclusions about the
lower rule-in potential of VCTE were shown in a retrospective study by Trowell et al. [25].
Harrison et al. demonstrated a lower performance of VCTE in the detection of significant
and advanced fibrosis among NASH patients (0.630 and 0.650, respectively) [20].
Another ultrasound-based imaging technique that demonstrated good accuracy with
AUROC ranging from 0.730 to 0.850 was SWE for detecting significant and advanced
fibrosis [22,26]. In the retrospective study conducted by Ozturk et al., SWE demonstrated
good accuracy in a small sample of NAFLD patients with very advanced liver fibrosis [22].
Slightly better diagnostic accuracy of SWE in the detection of significant and advanced
fibrosis was reported by Zhang et al. in their cross-sectional study conducted in the sample
of 100 NAFLD patients (AUROC of 0.810 and 0.850, respectively) [26].
A promising imaging diagnostic method is MRE, which computes transversal images
of liver tissue to capture the propagation of shear waves through the tissue. Results from
our SLR are in correlation with the previously published data. A retrospective study
conducted by Tang et al. reported very high diagnostic capabilities for the MRE technique
in the detection of advanced fibrosis among NAFLD patients (AUROC of 0.939–0.947 at
3.6–3.65 kPa cutoffs). However, this study was conducted on a small sample of patients
(19 patients) and the results should be further validated [39]. Zhang et al. compared
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diagnostic accuracy of MRE with SWE. Although MRE performed better in differentiating
lower stages of fibrosis (F1+ and F2+), there was no difference between the tools in detecting
F3+ fibrosis [40]. MRE was the only diagnostic tool captured in the SLR that tracked fibrosis
improvement or progression in patients with F2 or F3 fibrosis stage. Even though the study
had a small sample size and reported low sensitivity and specificity after 24 weeks from
baseline fibrosis measurement, the authors concluded that MRE-LSM could potentially
replace biopsy in evaluating longitudinal fibrosis changes [21].
The MRI-derived LSN score showed the lowest diagnostic accuracy for detecting
significant and advanced fibrosis among all imaging techniques captured in the SLR when
comparing the reported AUROCs. Despite a very high correlation between LSN score and
level of fibrosis in overweight and obese patients with biopsy-proven NAFLD, AUROC
values of 0.800 and 0.860 were the lowest compared to other imaging techniques [19].
Serum levels of liver enzymes AST and ALT are widely used blood biomarkers for the
diagnosis of multiple conditions. Due to their low cost and wide availability, they are used
to represent a starting point in fatty liver disease assessment [28]. However, the accuracy of
AST and ALT levels in predicting significant and advanced fibrosis may be affected by other
hepatic co-morbidities, patients’ characteristics, and associated conditions [41]. Accordingly,
Harrison et al. demonstrated modest diagnostic accuracy among the population of patients
diagnosed with NASH [20]. In contrast, Bril et al. suggest liver enzymes may remain
the main diagnostic biomarker of advanced fibrosis in patients with T2DM due to their
availability and high accuracy in excluding advanced cirrhosis, particularly in comparison
with more costly and more complicated diagnostic options that turn out to perform equally
well as AST/ALT levels in this population [28]. The authors recommended a sequential
approach incorporating AST followed by another noninvasive tool for detecting advanced
liver fibrosis, suggesting this approach would help avoid unnecessary liver biopsies [28].
Simple non-proprietary clinical scores (NFS, FIB-4, APRI) are cost-effective and sensitive enough to rule out the disease at lower thresholds. Still, they are not accurate enough
to confirm the diagnosis of advanced fibrosis. BARD score and GGT were inferior in the
detection of advanced fibrosis and showed modest accuracy with an AUROC in a range of
0.620–0.760 [20,27]. The Balakrishnan et al. study concluded that all investigated scores
(NFS, APRI, BARD, FIB-4) have a moderate discriminatory ability for advanced fibrosis
with AUROCs 0.700–0.790 [27] in predominantly Hispanic NAFLD patients. Similarly, the
findings from Marella et al.’s study implied that noninvasive scores may be unreliable in
the African American population and should be tested in larger multicenter studies [32].
Another study performed among T2DM patients with obesity also reported the modest
accuracy of the scores in this population, with only FIB-4 showing a trend toward better
accuracy [34]. Additionally, in a large observational study with more than two thousand
patients, Udelsman et al. demonstrated low specificity of all noninvasive scoring systems
in patients undergoing bariatric surgery [35]. Thus, although generally good accuracies
imply the scoring systems can be reliable tools for the detection of significant and advanced
fibrosis in everyday clinical practice, the modest performance in high-risk patients imposes
the need for a more reliable screening assessment.
More expensive techniques that evaluate direct fibrosis markers (i.e., fibrosis markers
in extracellular matrix components), such as the ELF test, CK-18 fragments, and PRO-C3,
demonstrated higher sensitivity in detecting significant and advanced fibrosis. Based
on our studies, these tests often cannot accurately differentiate progression or regression in diagnosed patients, and predominantly demonstrated modest diagnostic accuracy
(AUROC < 0.8). Harrison et al. reported that despite suboptimal performance of noninvasive biomarkers in general, ELF demonstrated somewhat better diagnostic ability in
fibrosis detection [20]. A large retrospective cohort analysis by Younossi et al. emphasized
that ELF may be a very valuable tool for advanced fibrosis detection with high NPV and
PPV but using multiple cohort-specific cutoff values that need to be validated before the
use in clinical practice [36].
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The FibroTest demonstrated modest diagnostic accuracy in the detection of advanced
fibrosis among T2DM patients [28]. The ADAPT score showed more promising results in
the detection of significant and advanced fibrosis within the sample of patients with NASH
and liver fibrosis [33]. The regression model developed by Kulkarni et al. demonstrated
very high accuracy in the detection of significant fibrosis among NAFLD patients [31]. Still,
the retrospective nature of the data and the lack of prospective validation prevent us from
concluding about the potential utility of the combined biomarkers.
In recent years, several specific metabolomic profiles have been associated with different stages of disease in NAFLD patients, making them a good target for future research in
NAFLD diagnostics. Further studies revealed that changes in levels of these metabolites
additionally could reflect specific pathways of liver injury related to NASH or advanced
fibrosis, making them compelling diagnostic biomarkers. Therefore, it has been suggested
that a combination of blood metabolites could be a highly accurate diagnostic test for the
detection of advanced fibrosis [29]. Furthermore, many researchers evaluated the diagnostic potential of different combinations of biomarkers and diagnostic scores for fibrosis
detection to achieve greater accuracy and better prediction power.
Caussy et al. demonstrated that a combination of 10 serum metabolites including
lipids, amino acids, and carbohydrates had a very good discriminatory ability for the
detection of advanced fibrosis among patients with biopsy-proven NAFLD [29]. The specific panel of blood biomarkers showed greater diagnostic accuracy with higher AUROC
values than the FIB-4 Index and NFS to detect advanced fibrosis, which was confirmed
afterwards in two independent validation cohorts. Moreover, the panel demonstrated
the ability to evaluate longitudinal changes in serum metabolites in assessing the disease
progression, which is a valuable characteristic rarely seen among biomarkers [29]. Harrison
et al. assessed the diagnostic accuracy of MCP-1 and liver fibrosis-specific protein [20], and
Corey et al. evaluated the diagnostic accuracy of NFPP and ADAMTSL2 in the detection of
significant and advanced fibrosis, aiming to detect the “protein-based signature of fibrosis” [30]. MCP-1 demonstrated a low level of diagnostic accuracy for detecting significant
and advanced fibrosis among NASH patients [20], while NFPP and ADAMTSL2 showed
promising results in the detection of advanced fibrosis among NAFLD patients (AUROC of
0.830) [30]. Decraecker et al. demonstrated in metabolic (dysfunction)-associated fatty liver
disease (MAFLD) patients with liver stiffness measurements, FIB-4, and LIVERFASt, that
noninvasive methods were correlated with overall and liver-related mortalities (p < 0.001),
and with all-cause and liver-related outcomes (p < 0.001) [42].
Studies captured in this SLR provide an insight into the new perspectives on diagnostic
tools and panels which combined imaging techniques and blood-based biomarkers for
detecting significant fibrosis. The FAST score is a novel technique that combines liver
stiffness measurement and controlled attenuation parameters measured by VCTE and
serum levels of AST. That score was already established in a European cohort and Woreta
et al. validated the results in the US population [38]. The FAST score demonstrated
high diagnostic accuracy in the detection of significant fibrosis among NAFLD patients.
Still, the modest PPV implies the score should be interpreted carefully when ruling in
patients with significant fibrosis [38]. The other novel technique established by Jung
et al. demonstrated even better diagnostic accuracy of the MEFIB index, and MRE liver
examination in combination with the FIB-4 index, for detecting significant fibrosis among
NAFLD patients [37].
Our findings are in line with the results of other studies. Chalasani et al. reported
that 27% of patients evaluated with VCTE yielded unreliable results [43] while a European
retrospective study demonstrated the high accuracy of VCTE with an AUROC of 0.800 at
9.9 kPa and 11.4 kPa cutoff values for the detection of advanced fibrosis among patients
with biopsy-proven NASH [44]. A previously published meta-analysis comparing the
accuracy of VCTE and MRE in fibrosis detection concluded that MRE provides significantly
greater accuracy, although both methods performed very well in NAFLD patients [45].
However, despite the good reliability of MRE in detecting and differentiating liver fibrosis,
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the decision to use one method over another depends on multiple factors, including
the availability of the tool and cost-effectiveness. MRE also requires special equipment,
software, additional hardware beyond routine scanners, as well as experienced experts
for results validation and interpretation [46]. Thus, it is unlikely that MRE will replace
US-based imaging methods for the detection and longitudinal tracking of liver fibrosis in
routine clinical practice in the near future. The overarching pitfall of all imaging methods
is unreliable specificity and dependence on the screener’s experience and subjectivity in
determining the fibrosis stage. Furthermore, imaging techniques may be non-standardized,
costly, not widely available, or inaccessible [45].
Similarly, although multiple noninvasive biomarkers are available on the market
for detecting significant or advanced liver fibrosis, there is still an unmet need for a
test that would provide more accurate staging and differentiation of fibrosis as currently
used noninvasive tests remain inconclusive in approximately 30% of patients [47]. The
Noninvasive Biomarkers of Metabolic Liver Disease (NIMBLE) consortium demonstrated
that only NIS4, ELF test, and FibroMeter-VCTE met the predefined criteria (AUROC > 0.800)
for accurate diagnosis of significant fibrosis (F2+ stages), while the ELF test and FibroMeterVCTE met criteria for successful determination of advanced fibrosis (F3+ stages). Other
investigated tests (FIB-4 index, serum ALT levels, OWLiver, and serum PRO-C3 levels)
did not satisfy the criteria in terms of diagnostic accuracy in the detection of F2+ and F3+
fibrosis stages [48]. No diagnostic test addressed the unmet need in terms of diagnostic
tool sensitivity and specificity of >80% in the detection of any stage of fibrosis, which was
the minimum acceptable level specified by payers in the US. Of all evaluated diagnostic
panels, only NIS4 for the detection of significant fibrosis and FibroMeter-VCTE for the
detection of advanced fibrosis met the criteria specified by the US healthcare providers
(sensitivity and specificity > 75%) [48]. The European Association for the Study of the
Liver (EASL) clinical practice guidelines for NASH listed several reliable biomarkers for
fibrosis detection with AUROC values higher than 0.8, including NFS, FIB-4 index, ELF,
and FibroTest [49,50]. Apart from fibrosis detection, the tests also predicted liver-related
and overall mortality with good precision. Still, the guidelines emphasize that the tests
can correctly distinguish advanced fibrosis from lower stages, but not significant fibrosis.
Additionally, the high NPV show that the tests perform particularly well in excluding
advanced fibrosis so that they can be used as a first-line strategy in risk stratification, while
they are not as good in ruling in fibrosis [49]. The study points out that predictive values
are highly dependent on fibrosis prevalence in the study population, which is generally
higher than in the community. Thus, the generalizability of the study findings would need
to be tested in larger populations of patients [49]. A recently published review reports on
the use of serum fibrosis biomarkers based on routine biochemistry and VCTE as validated
and well-incorporated screening strategies for identifying high-risk patients. Still, MRI
techniques are seen as the most promising noninvasive diagnostic strategy as they offer
accurate fibrosis staging with the ability to assess therapeutic response [51]. Finally, a
systematic review of available guidelines for NAFLD assessment concludes that fibrosis
scores may help detect high-risk patients who may be referred to liver biopsy; still, all
guidelines stress the necessity of developing a noninvasive test that will replace liver biopsy
as a research priority [52].
Liver biopsy remains the reference standard in fibrosis detection and classification [53,54].
However, a growing body of evidence highlights the limitations of liver biopsy, particularly
in fibrosis detection [55]. Aside from the risk of complications and invasive nature, sampling
variability remains a big concern as histological lesions are unevenly distributed throughout
the liver tissue [56]. Further problems with pathological diagnosis arise with inter- and
intra-observer variability. Therefore, evaluating test accuracy with an imperfect reference
standard such as a liver biopsy poses the risk of underestimating NASH and fibrosis
severity [55].
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Study Strengths and Limitations
The major strength of this review is that this is the first study to systematically summarize and compare noninvasive diagnostic tools evaluated in the US healthcare context. As
the majority of noninvasive diagnostic tools were compared to the biopsy gold standard,
this review collects clinically relevant evidence, establishing basis for decision making
in the field. This SLR has several limitations. As in all literature reviews, it has to be
acknowledged that the reliability of the findings depends on the methodology and validity
of the primary studies. Only diagnostic tools with either sensitivity or specificity values
were presented in the Results section. The SLR considered only two literature databases,
PubMed and Web of Science. Another limitation is the heterogeneity of the included studies
that prevented us from synthesizing quantitative evidence and providing narrow point
estimates of the effective measures. This review aimed to systematically summarize the
recent trends in clinical practice and diagnostic research in NAFLD, identifying articles
published from 2016 onwards. It has to be denoted that the review may have omitted
promising research tools published prior to 2016. Thus, the study results were discussed
and interpreted with caution, paying particular attention to the existing body of evidence
and ensuring the conclusions are in line with findings from previous systematic literature
reviews [10,47,57,58]. Some of the included studies were conducted in small population
samples; therefore, the demonstrated results may lack generalizability. Additionally, some
diagnostic tools were assessed in only one published article, so the findings have to be
interpreted with caution until confirmed in larger observational studies. Furthermore,
the lack of direct head-to-head comparisons between the diagnostic strategies limits the
possibility of unbiased comparison of diagnostic accuracy between the tools. Our study
concentrated on the diagnostic ability of noninvasive tools to identify and differentiate
significant and advanced fibrosis (F2+ and F3+), stipulating that the diagnosis made at this
stage may impact clinical decision-making and change the course of the disease. Still, the
efficiency of the tools in detecting earlier stages of fibrosis (F1+) has not been reviewed,
while it may be increasingly important in the disease course, as treatment measures at
earlier stages may positively impact the disease outcomes [59]. Additionally, some of
the multicenter studies cited here did not have a centralized pathological reading, which
then introduces substantial bias in relation to inter-pathologist variability. Finally, quality
assessment and critical appraisal of the studies were not performed. The SLR presents
only formally published data, which may lead to publication bias, as journals are strongly
biased towards publishing only the studies that report significant differences in the results.
Still, as the SLR was not primarily focused on treatment effectiveness, the probability of
bias in our review is low.
5. Conclusions
Liver fibrosis detection, staging, and monitoring represent crucial points in the clinical
assessment and risk evaluation of patients with nonalcoholic liver disease, as it is the major
predictor of patients’ morbidity and mortality. Imaging techniques represent an important
part of the management of patients with suspected liver fibrosis, becoming increasingly
incorporated into routine clinical practice. Imaging techniques overcome limitations of
liver biopsy, such as discomfort, invasiveness, and repeated tissue sampling, providing
good overall accuracy in fibrosis detection. However, they are still not able to provide
a sufficiently sensitive and reliable estimate of quantitative longitudinal and dynamic
changes in fibrosis development and regression. Moreover, advanced imaging techniques
like VCTE and MRE require costly equipment and trained personnel, so they are less
available in clinical practices across the country.
Observing the wide spectrum of available biomarkers, including clinical scores and
panels that combine several blood tests, it may be correctly concluded that noninvasive
biomarkers play a significant and ever-increasing role in detecting liver fibrosis in patients
with NAFLD, including high-risk subgroups of patients. On the other hand, observing the
high sensitivity, specificity, and AUROC values presented in the studies, it could be falsely
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concluded that there are tools with almost perfect diagnostic abilities that may detect liver
fibrosis with a precision equivalent to substantially more expensive imaging methods or
even biopsy. Still, in reality, the perfect noninvasive biomarker has not been established
so far. In general, noninvasive biomarkers demonstrated very good accuracy in excluding
significant or advanced liver fibrosis. The highest accuracy was observed among scores
that combine several biomarkers, metabolites, and clinical parameters. Still, the studies
generally conclude that all these tests have limited power in detecting and quantifying
fibrosis levels, which is necessary for patient management and monitoring of disease
progression. Several innovative technologies that demonstrated promising initial results in
small patient cohorts have to be externally validated in wider independent studies. There is
still an unmet need for a noninvasive biomarker that can detect, measure, and differentiate
fibrosis stages with great sensitivity and specificity. Additionally, the optimal diagnostic
tool has to be easily applicable and affordable for patients, providers, and healthcare centers
at all levels, due to the rising prevalence of the disease among all age categories, ethnicities,
and risk groups. Nonetheless, because of the variability of the biopsy itself as well as of
the pathological reading, the ultimate validation of noninvasive markers will involve their
ability to predict clinical events rather than a particular histological lesion.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/diagnostics12112608/s1, Table S1: Search strategy.
Author Contributions: Conceptualization, D.G. and V.Z.; methodology, F.S., D.V. and V.Z.; software,
F.S. and D.V.; validation, D.G., F.S., D.V., V.Z. and T.T.; formal analysis, F.S. and D.V.; investigation,
all authors; resources, D.G.; data curation, F.S.; writing—original draft preparation, F.S. and D.V.;
writing—review and editing, all authors; visualization, F.S. and D.V.; supervision, D.G., V.Z. and T.T.;
project administration, D.G. and V.Z.; funding acquisition, D.G. All authors have read and agreed to
the published version of the manuscript.
Funding: This research was funded by Glympse Bio.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: D.G. is an employee of Glympse Bio. V.R. discloses consulting for NovoNordisk, Terns, Madrigal, Enyo, Poxel, Bristol-Myers-Squibb, Intercept, NGM, Pfizer France. F.S.,
D.V., and V.Z. received financial support from Glympse Bio for conducting the study. N.G. has
nothing to disclose. HDM.D. is a consultant for Glympse Bio and Pfizer and has received research
grants from Intercept, BMS, Novo Nordisk, Viking, Pfizer, Galectin. T.T. is an employee of Glympse
Bio, consultant for Gilead Sciences, and Independent Board Director at Arbutus Biopharma.

References
1.
2.

3.
4.
5.
6.
7.

Yu, J.; Marsh, S.; Hu, J.; Feng, W.; Wu, C. The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut
Microbiota, and Genetic Background. Gastroenterol. Res. Pract. 2016, 2016, 2862173. [CrossRef] [PubMed]
Gadiparthi, C.; Spatz, M.; Greenberg, S.; Iqbal, U.; Kanna, S.; Satapathy, S.K.; Broder, A.; Ahmed, A. NAFLD Epidemiology,
Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. J. Clin. Transl. Hepatol. 2020,
8, 215–221. [CrossRef] [PubMed]
Zou, B.; Yeo, Y.H.; Nguyen, V.H.; Cheung, R.; Ingelsson, E.; Nguyen, M.H. Prevalence, characteristics and mortality outcomes of
obese, nonobese and lean NAFLD in the United States, 1999–2016. J. Intern. Med. 2020, 288, 139–151. [CrossRef]
Caldwell, S.; Ikura, Y.; Dias, D.; Isomoto, K.; Yabu, A.; Moskaluk, C.; Pramoonjago, P.; Simmons, W.; Scruggs, H.; Rosenbaum, N.;
et al. Hepatocellular ballooning in NASH. J. Hepatol. 2010, 53, 719–723. [CrossRef]
Carr, R.M.; Oranu, A.; Khungar, V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol. Clin. N.
Am. 2016, 45, 639–652. [CrossRef]
Parthasarathy, G.; Revelo, X.; Malhi, H. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. Hepatol. Commun. 2020,
4, 478–492. [CrossRef] [PubMed]
Younossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global burden of NAFLD and
NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 11–20. [CrossRef]

Diagnostics 2022, 12, 2608

8.
9.

10.

11.

12.

13.

14.

15.
16.
17.

18.
19.

20.

21.

22.

23.

24.

25.
26.

27.

28.

24 of 26

Dufour, J.-F.; Scherer, R.; Balp, M.-M.; McKenna, S.J.; Janssens, N.; Lopez, P.; Pedrosa, M. The global epidemiology of nonalcoholic
steatohepatitis (NASH) and associated risk factors—A targeted literature review. Endocr. Metab. Sci. 2021, 3, 100089. [CrossRef]
Hayashi, T.; Saitoh, S.; Fukuzawa, K.; Tsuji, Y.; Takahashi, J.; Kawamura, Y.; Akuta, N.; Kobayashi, M.; Ikeda, K.; Fujii, T.; et al.
Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. Gut
Liver 2017, 11, 674–683. [CrossRef]
Younossi, Z.M.; Loomba, R.; Anstee, Q.M.; Rinella, M.E.; Bugianesi, E.; Marchesini, G.; Neuschwander-Tetri, B.A.; Serfaty, L.;
Negro, F.; Caldwell, S.H.; et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and
associated fibrosis. Hepatology 2018, 68, 349–360. [CrossRef]
Lee, T.H.; Peters, J.J. Hepatic Fibrosis: MSD Manual Professional Version. 2022. Available online: https://www.msdmanuals.
com/professional/hepatic-and-biliary-disorders/fibrosis-and-cirrhosis/hepatic-fibrosis?query=hepatic%20fibrosis (accessed on
25 July 2022).
García-Compeán, D.; Villarreal-Pérez, J.Z.; Cavazos, M.E.O.; Lavalle-Gonzalez, F.J.; Borjas-Almaguer, O.D.; Del Cueto-Aguilera,
A.N.; González-González, J.A.; Treviño-Garza, C.; Huerta-Pérez, L.; Maldonado-Garza, H.J. Prevalence of liver fibrosis in an
unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? Ann. Hepatol. 2020,
19, 258–264. [CrossRef] [PubMed]
Arab, J.P.; Barrera, F.; Gallego, C.; Valderas, J.P.; Uribe, S.; Tejos, C.; Serrano, C.; Serrano, C.; Huete, Á.; Liberona, J.; et al. High
prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients. Ann. Hepatol. 2016, 15, 721–728.
[PubMed]
Dvorak, K.; Stritesky, J.; Petrtyl, J.; Vitek, L.; Sroubkova, R.; Lenicek, M.; Smid, V.; Haluzik, M.; Bruha, R. Use of non-invasive
parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice—An exploratory case-control study. PLoS ONE
2014, 9, e111551. [CrossRef] [PubMed]
Ciardullo, S.; Perseghin, G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States
population. Liver Int. 2021, 41, 1290–1293. [CrossRef] [PubMed]
Ekstedt, M.; Hagström, H.; Nasr, P.; Fredrikson, M.; Stål, P.; Kechagias, S.; Hultcrantz, R. Fibrosis stage is the strongest predictor
for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015, 61, 1547–1554. [CrossRef]
Dulai, P.S.; Singh, S.; Patel, J.; Soni, M.; Prokop, L.J.; Younossi, Z.; Sebastiani, G.; Ekstedt, M.; Hagstrom, H.; Nasr, P.; et al.
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology
2017, 65, 1557–1565. [CrossRef]
Rockey, D.C.; Bissell, D.M. Noninvasive measures of liver fibrosis. Hepatology 2006, 43 (Suppl. S1), S113–S120. [CrossRef]
Catania, R.; Furlan, A.; Smith, A.D.; Behari, J.; Tublin, M.E.; Borhani, A.A. Diagnostic value of MRI-derived liver surface nodularity
score for the non-invasive quantification of hepatic fibrosis in non-alcoholic fatty liver disease. Eur. Radiol. 2021, 31, 256–263.
[CrossRef]
Harrison, S.A.; Calanna, S.; Cusi, K.; Linder, M.; Okanoue, T.; Ratziu, V.; Sanyal, A.; Sejling, A.S.; Newsome, P.N. Semaglutide for
the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. Contemp. Clin. Trials
2020, 97, 106174. [CrossRef]
Jayakumar, S.; Middleton, M.S.; Lawitz, E.J.; Mantry, P.S.; Caldwell, S.H.; Arnold, H.; Mae Diehl, A.; Ghalib, R.; Elkhashab, M.;
Abdelmalek, M.F.; et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic
steatohepatitis: Analysis of data from a phase II trial of selonsertib. J. Hepatol. 2019, 70, 133–141. [CrossRef]
Ozturk, A.; Mohammadi, R.; Pierce, T.T.; Kamarthi, S.; Dhyani, M.; Grajo, J.R.; Corey, K.E.; Chung, R.T.; Bhan, A.K.; Chhatwal, J.;
et al. Diagnostic Accuracy of Shear Wave Elastography as a Non-Invasive Biomarker of High-Risk Non-Alcoholic Steatohepatitis
in Patients with Non-Alcoholic Fatty Liver Disease. Ultrasound Med. Biol. 2020, 46, 972–980. [CrossRef] [PubMed]
Siddiqui, M.S.; Idowu, M.O.; Stromberg, K.; Sima, A.; Lee, E.; Patel, S.; Ghaus, S.; Driscoll, C.; Sterling, R.K.; John, B.; et al.
Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients. Clin. Gastroenterol.
Hepatol. 2021, 19, 367–374. [CrossRef] [PubMed]
Tang, A.; Dzyubak, B.; Yin, M.; Schlein, A.; Henderson, W.C.; Hooker, J.C.; Delgado, T.I.; Middleton, M.S.; Zheng, L.; Wolfson, T.;
et al. MR elastography in nonalcoholic fatty liver disease: Inter-center and inter-analysis-method measurement reproducibility
and accuracy at 3T. Eur. Radiol. 2022, 32, 2937–2948. [CrossRef] [PubMed]
Trowell, J.; Alukal, J.; Zhang, T.; Liu, L.; Maheshwari, A.; Yoo, H.Y.; Thuluvath, P.J. How Good Are Controlled Attenuation
Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? Dig. Dis. Sci. 2021, 66, 1297–1305. [CrossRef] [PubMed]
Zhang, Y.N.; Fowler, K.J.; Boehringer, A.S.; Montes, V.; Schlein, A.N.; Covarrubias, Y.; Wolfson, T.; Hong, C.W.; Valasek, M.A.;
Andre, M.P.; et al. Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance
elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. Eur. Radiol. 2022,
32, 2457–2469. [CrossRef]
Balakrishnan, M.; Seth, A.; Cortes-Santiago, N.; Jain, S.; Sood, G.K.; El-Serag, H.B.; Thrift, A.P. External Validation of Four
Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population.
Dig. Dis. Sci. 2021, 66, 2387–2393. [CrossRef]
Bril, F.; McPhaul, M.J.; Caulfield, M.P.; Clark, V.C.; Soldevilla-Pico, C.; Firpi-Morell, R.J.; Lai, J.; Shiffman, D.; Rowland, C.M.;
Cusi, K. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in
Patients with Type 2 Diabetes. Diabetes Care 2020, 43, 290–297. [CrossRef]

Diagnostics 2022, 12, 2608

29.

30.

31.
32.

33.

34.

35.
36.

37.

38.

39.
40.

41.
42.

43.

44.

45.

46.
47.
48.

49.

25 of 26

Caussy, C.; Ajmera, V.H.; Puri, P.; Hsu, C.L.; Bassirian, S.; Mgdsyan, M.; Singh, S.; Faulkner, C.; Valasek, M.A.; Rizo, E.; et al.
Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic
fatty liver disease. Gut 2019, 68, 1884–1892. [CrossRef]
Corey, K.E.; Pitts, R.; Lai, M.; Loureiro, J.; Masia, R.; Osganian, S.A.; Gustafson, J.L.; Hutter, M.M.; Gee, D.W.; Meireles, O.R.; et al.
ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with
NAFLD. J. Hepatol. 2022, 76, 25–33. [CrossRef]
Kulkarni, S.; Naz, N.; Gu, H.; Stoll, J.M.; Thompson, M.D.; DeBosch, B.J. A clinical model to predict fibrosis on liver biopsy in
paediatric subjects with nonalcoholic fatty liver disease. Clin. Obes. 2021, 11, e12472. [CrossRef]
Marella, H.K.; Reddy, Y.K.; Jiang, Y.; Ganguli, S.; Podila, P.S.B.; Snell, P.D.; Kovalic, A.J.; Cholankeril, G.; Singal, A.K.; Nair, S.;
et al. Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients with Nonalcoholic Fatty Liver
Disease. Clin. Transl. Gastroenterol. 2020, 11, e00165. [CrossRef] [PubMed]
Nielsen, M.J.; Leeming, D.J.; Goodman, Z.; Friedman, S.; Frederiksen, P.; Rasmussen, D.G.K.; Vig, P.; Seyedkazemi, S.; Fischer, L.;
Torstenson, R.; et al. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the
CENTAUR screening population. J. Hepatol. 2021, 75, 1292–1300. [CrossRef] [PubMed]
Singh, A.; Gosai, F.; Siddiqui, M.T.; Gupta, M.; Lopez, R.; Lawitz, E.; Poordad, F.; Carey, W.; McCullough, A.; Alkhouri, N.
Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients with Type-2 Diabetes with Biopsy-Proven
Nonalcoholic Fatty Liver Disease. J. Clin. Gastroenterol. 2020, 54, 891–897. [CrossRef] [PubMed]
Udelsman, B.V.; Corey, K.; Hutter, M.M.; Chang, D.C.; Witkowski, E.R. Use of noninvasive scores for advanced liver fibrosis can
guide the need for hepatic biopsy during bariatric procedures. Surg. Obes. Relat. Dis. 2021, 17, 292–298. [CrossRef]
Younossi, Z.M.; Felix, S.; Jeffers, T.; Younossi, E.; Nader, F.; Pham, H.; Afendy, A.; Cable, R.; Racila, A.; Younoszai, Z.; et al.
Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis among Patients with Nonalcoholic Fatty Liver
Disease. JAMA Netw. Open 2021, 4, e2123923. [CrossRef]
Jung, J.; Loomba, R.R.; Imajo, K.; Madamba, E.; Gandhi, S.; Bettencourt, R.; Singh, S.; Hernandez, C.; Valasek, M.A.; Behling, C.;
et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
Gut 2021, 70, 1946–1953. [CrossRef]
Woreta, T.A.; Van Natta, M.L.; Lazo, M.; Krishnan, A.; Neuschwander-Tetri, B.A.; Loomba, R.; Mae Diehl, A.; Abdelmalek, M.F.;
Chalasani, N.; Gawrieh, S.; et al. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic
steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS ONE 2022, 17, e0266859.
[CrossRef]
Costa-Silva, L.; Ferolla, S.M.; Lima, A.S.; Vidigal, P.V.T.; Ferrari, T.C.A. MR elastography is effective for the non-invasive evaluation of
fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. Eur. J. Radiol. 2018, 98, 82–89. [CrossRef]
Dyvorne, H.A.; Jajamovich, G.H.; Bane, O.; Fiel, M.I.; Chou, H.; Schiano, T.D.; Dieterich, D.; Babb, J.S.; Friedman, S.L.; Taouli, B.
Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection.
Liver Int. 2016, 36, 659–666. [CrossRef]
Giannini, E.G.; Testa, R.; Savarino, V. Liver enzyme alteration: A guide for clinicians. Can. Med. Assoc. J. 2005, 172, 367–379.
[CrossRef]
Decraecker, M.; Dutartre, D.; Hiriart, J.B.; Irles-Depé, M.; Chermak, F.; Foucher, J.; de Lédinghen, V. Long-term prognosis of
patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods. Aliment. Pharmacol. Ther. 2022,
55, 580–592. [CrossRef]
Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis
and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver
Diseases. Hepatology 2018, 67, 328–357. [CrossRef] [PubMed]
Anstee, Q.M.; Lawitz, E.J.; Alkhouri, N.; Wong, V.W.; Romero-Gomez, M.; Okanoue, T.; Trauner, M.; Kersey, K.; Li, G.; Han, L.;
et al. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data from the STELLAR Trials. Hepatology
2019, 70, 1521–1530. [CrossRef] [PubMed]
Hsu, C.; Caussy, C.; Imajo, K.; Chen, J.; Singh, S.; Kaulback, K.; Le, M.D.; Hooker, J.; Tu, X.; Bettencourt, R.; et al. Magnetic
Resonance vs. Transient Elastography Analysis of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and
Pooled Analysis of Individual Participants. Clin. Gastroenterol. Hepatol. 2019, 17, 630–637.e8. [CrossRef] [PubMed]
Smith, A.D.; Porter, K.K.; Elkassem, A.A.; Sanyal, R.; Lockhart, M.E. Current Imaging Techniques for Noninvasive Staging of
Hepatic Fibrosis. AJR Am. J. Roentgenol. 2019, 213, 77–89. [CrossRef]
Vilar-Gomez, E.; Chalasani, N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and
blood-based biomarkers. J. Hepatol. 2018, 68, 305–315. [CrossRef]
Sanyal, A.J.; Shankar, S.S.; Yates, K.; Daly, E.; Bolognese, J.A.; Neuschwander-Tetri, B.A.; Kowdley, K.V.; Vuppalanchi, R.; Guy, C.A.;
Tonascia, J.; et al. Primary Results of the NIMBLE Stage 1-NASH CRN Study of Circulating Biomarkers for Nonalcoholic Steatohepatitis and
Its Activity and Fibrosis Stage; American Association for the Study of Liver Diseases: Washington, DC, USA, 2021.
European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the
Study of Obesity. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J.
Hepatol. 2016, 64, 1388–1402. [CrossRef]

Diagnostics 2022, 12, 2608

50.
51.
52.
53.
54.
55.
56.
57.
58.
59.

26 of 26

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver
disease severity and prognosis—2021 update. J. Hepatol. 2021, 75, 659–689. [CrossRef]
Hydes, T.; Brown, E.; Hamid, A.; Bateman, A.C.; Cuthbertson, D.J. Current and Emerging Biomarkers and Imaging Modalities for
Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. Clin. Ther. 2021, 43, 1505–1522. [CrossRef]
Monelli, F.; Venturelli, F.; Bonilauri, L.; Manicardi, E.; Manicardi, V.; Rossi, P.G.; Massari, M.; Ligabue, G.; Riva, N.; Schianchi, S.;
et al. Systematic review of existing guidelines for NAFLD assessment. Hepatoma Res. 2021, 7, 25. [CrossRef]
Younossi, Z.M.; Stepanova, M.; Younossi, Y.; Golabi, P.; Mishra, A.; Rafiq, N.; Henry, L. Epidemiology of chronic liver diseases in
the USA in the past three decades. Gut 2020, 69, 564–568. [CrossRef] [PubMed]
Rowe, I.A. Too much medicine: Overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol. Hepatol.
2018, 3, 66–72. [CrossRef]
Lee, J.; Vali, Y.; Boursier, J.; Spijker, R.; Anstee, Q.M.; Bossuyt, P.M.; Zafarmand, M.H. Prognostic accuracy of FIB-4, NAFLD
fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int. 2021, 41, 261–270. [CrossRef]
Ratziu, V.; Charlotte, F.; Heurtier, A.; Gombert, S.; Giral, P.; Bruckert, E.; Grimaldi, A.; Capron, F.; Poynard, T. Sampling variability
of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128, 1898–1906. [CrossRef]
Byrne, C.D.; Patel, J.; Scorletti, E.; Targher, G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. Bmj
2018, 362, k2734. [CrossRef]
Jensen, T.; Wieland, A.; Cree-Green, M.; Nadeau, K.; Sullivan, S. Clinical workup of fatty liver for the primary care provider.
Postgrad. Med. 2019, 131, 19–30. [CrossRef] [PubMed]
Fujimori, N.; Kimura, T.; Tanaka, N.; Yamazaki, T.; Okumura, T.; Kobayashi, H.; Wakabayashi, S.I.; Yamashita, Y.; Sugiura, A.;
Pham, J.; et al. 2-Step PLT16-AST44 method: Simplified liver fibrosis detection system in patients with non-alcoholic fatty liver
disease. Hepatol. Res. 2022, 52, 352–363. [CrossRef] [PubMed]

